AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2563839 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 164
Study 2563839 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortography
Number of subjects: 164
Study 31340760 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 50 mg (SPARTAN only)
Number of subjects: 3981
Study 31340760 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Number of subjects: 3981
Study 31340760 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Number of subjects: 3981
Study 31340760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3981
Study 31340760 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan (all doses)
Number of subjects: 3981
Study 31340760 — intervention group
Group type: COMPARATOR
Intervention: Lasmiditan and Placebo
Number of subjects: 3981
Study 27997285 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed messages
Number of subjects: 132
Study 27997285 — intervention group
Group type: COMPARATOR
Intervention: Loss-framed messages
Number of subjects: 132
Study 27997285 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term consequences
Number of subjects: 132
Study 27997285 — intervention group
Group type: COMPARATOR
Intervention: Long-term consequences
Number of subjects: 132
Study 25569654 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl combined with etomidate (fentanyl 1 to 2 μg/kg, etomidate 0.1 to 0.3 mg/kg)
Number of subjects: 0
Study 25569654 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine only (control group)
Number of subjects: 0
Study 23132201 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive physician affect
Number of subjects: 227
Study 23132201 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer visits
Number of subjects: 227
Study 21262883 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive‐pressure ventilation (NIPPV)
Number of subjects: 200
Study 21262883 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 200
Study 21262883 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPPV
Number of subjects: 200
Study 21262883 — intervention group
Group type: COMPARATOR
Intervention: NCPAP
Number of subjects: 200
Study 21262883 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPPV (in infants who received surfactant therapy)
Number of subjects: 200
Study 21262883 — intervention group
Group type: COMPARATOR
Intervention: NCPAP (in infants who received surfactant therapy)
Number of subjects: 200
Study 19333158 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin sensitization
Number of subjects: 125
Study 19333158 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol sensitization
Number of subjects: 125
Study 19333158 — intervention group
Group type: COMPARATOR
Intervention: Control (nonsensitized)
Number of subjects: 125
Study 17107540 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive glass S53P4 (BAG)
Number of subjects: 23
Study 17107540 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide
Number of subjects: 23
Study 15100715 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein, high-sodium diet (90 g protein/day, 180 mmol sodium/day)
Number of subjects: 18
Study 15100715 — intervention group
Group type: COMPARATOR
Intervention: Moderate-protein, low-sodium diet (70 g protein/day, 65 mmol sodium/day)
Number of subjects: 18
Study 11059910 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam treatment
Number of subjects: 0
Study 11059910 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized prime in a flickering 40-Hz display matrix
Number of subjects: 0
Study 11059910 — intervention group
Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 0
Study 9106934 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral collagen type II (CII) treatment at 10 mg per day
Number of subjects: 0
Study 9106934 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral collagen type II (CII) treatment at 1 mg per day
Number of subjects: 0
Study 9106934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8348277 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg of i.m. depot methylprednisolone acetate (MPA)
Number of subjects: 41
Study 8348277 — intervention group
Group type: COMPARATOR
Intervention: 500 mg methylprednisolone (MP) orally
Number of subjects: 41
Study 2883004 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine JNIH‐6
Number of subjects: 67
Study 2883004 — intervention group
Group type: COMPARATOR
Intervention: Placebo (carrier solution of aluminium phosphate)
Number of subjects: 67
Study 29751193 — intervention group
Group type: EXPERIMENTAL
Intervention: Low added sugar adequate fiber diet (LASAF; 5% total energy from AS and 13.5 g fiber/1000 kcal)
Number of subjects: 32
Study 29751193 — intervention group
Group type: COMPARATOR
Intervention: High added sugar low fiber diet (HASLF; 25% total energy from AS and 8.2 g/1000 kcal)
Number of subjects: 32
Study 26496853 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAF-mutated index TSAs
Number of subjects: 111
Study 26496853 — intervention group
Group type: EXPERIMENTAL
Intervention: CRCs
Number of subjects: 111
Study 24992068 — intervention group
Group type: EXPERIMENTAL
Intervention: Short stem prosthesis (Fitmore; Zimmer)
Number of subjects: 80
Study 24992068 — intervention group
Group type: COMPARATOR
Intervention: Conventional straight stem prosthesis (CLS; Zimmer)
Number of subjects: 80
Study 22691145 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed self-regulated learning (DSRL)
Number of subjects: 42
Study 22691145 — intervention group
Group type: COMPARATOR
Intervention: Instructor-regulated learning (IRL)
Number of subjects: 42
Study 20417426 — intervention group
Group type: EXPERIMENTAL
Intervention: Minihysteroscopy with saline solution
Number of subjects: 184
Study 20417426 — intervention group
Group type: EXPERIMENTAL
Intervention: Minihysteroscopy with CO(2)
Number of subjects: 184
Study 20417426 — intervention group
Group type: COMPARATOR
Intervention: Conventional hysteroscopy with saline solution
Number of subjects: 184
Study 20417426 — intervention group
Group type: COMPARATOR
Intervention: Conventional hysteroscopy with CO(2)
Number of subjects: 184
Study 18538402 — intervention group
Group type: COMPARATOR
Intervention: Monofocal IOL (AR 40)
Number of subjects: 62
Study 18538402 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal IOLs (Array SA40N, ReZoom, Tecnis ZM900)
Number of subjects: 62
Study 18538402 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffractive multifocal IOL (Tecnis ZM900)
Number of subjects: 62
Study 18538402 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal refractive IOL (Array SA40N)
Number of subjects: 62
Study 18538402 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal refractive IOL (ReZoom)
Number of subjects: 62
Study 18538402 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal diffractive IOL (Tecnis ZM900)
Number of subjects: 62
Study 18538402 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffractive multifocal IOL
Number of subjects: 62
Study 18538402 — intervention group
Group type: EXPERIMENTAL
Intervention: Refractive multifocal IOLs
Number of subjects: 62
Study 18538402 — intervention group
Group type: COMPARATOR
Intervention: Monofocal IOL
Number of subjects: 62
Study 15914535 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 microg
Number of subjects: 38
Study 15914535 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 40 microg
Number of subjects: 38
Study 15914535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 12872556 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin treatment (n = 96)
Number of subjects: 191
Study 12872556 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 95)
Number of subjects: 191
Study 10572078 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN)
Number of subjects: 152
Study 10572078 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 152
Study 10572078 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan
Number of subjects: 152
Study 10572078 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN) within 90 days before BMT
Number of subjects: 152
Study 10572078 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN) discontinued more than 90 days before BMT
Number of subjects: 152
Study 8537688 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine (50 mg) with folinic acid (15 mg) given three times weekly
Number of subjects: 554
Study 8537688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 554
Study 1907074 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (200 micrograms intravenous)
Number of subjects: 0
Study 1907074 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (400 micrograms intravenous)
Number of subjects: 0
Study 1907074 — intervention group
Group type: COMPARATOR
Intervention: Thyrotropin-releasing hormone
Number of subjects: 0
Study 7051244 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim (TMP) 320 mg plus Sulfamethoxazole (SMZ) 1,600 mg daily for 14 days
Number of subjects: 20
Study 7051244 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin 2 g daily for 14 days
Number of subjects: 20
Study 31182258 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive functional rehabilitation (IFR) program
Number of subjects: 104
Study 31182258 — intervention group
Group type: COMPARATOR
Intervention: Standard care only (Control)
Number of subjects: 104
Study 30496879 — intervention group
Group type: EXPERIMENTAL
Intervention: Shimming across entire patient volumes
Number of subjects: 21
Study 30496879 — intervention group
Group type: EXPERIMENTAL
Intervention: User-defined region of interest (ROI) shimming strategy
Number of subjects: 21
Study 30496879 — intervention group
Group type: COMPARATOR
Intervention: MRI geometric distortions
Number of subjects: 21
Study 30496879 — intervention group
Group type: COMPARATOR
Intervention: Dose differences between dCT and CT treatment plans
Number of subjects: 21
Study 28129130 — intervention group
Group type: EXPERIMENTAL
Intervention: Revusiran (GalNAc-siRNA conjugate) at doses of 2.5-10 mg/kg
Number of subjects: 0
Study 28129130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26575246 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic cystectomy
Number of subjects: 32
Study 26575246 — intervention group
Group type: COMPARATOR
Intervention: Traditional Sistrunk's surgery
Number of subjects: 32
Study 23892043 — intervention group
Group type: EXPERIMENTAL
Intervention: PHQ completed before meeting with medical provider (experimental group)
Number of subjects: 101
Study 23892043 — intervention group
Group type: COMPARATOR
Intervention: PHQ completed after meeting with medical provider (control group)
Number of subjects: 101
Study 21417591 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 42
Study 21417591 — intervention group
Group type: COMPARATOR
Intervention: Air-abrasive treatment
Number of subjects: 42
Study 19296243 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenectomy
Number of subjects: 216
Study 19296243 — intervention group
Group type: COMPARATOR
Intervention: Spleen-preserving
Number of subjects: 216
Study 17574448 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 112
Study 17574448 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 112
Study 17574448 — intervention group
Group type: COMPARATOR
Intervention: Valproate
Number of subjects: 112
Study 17574448 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine/Valproate
Number of subjects: 112
Study 16027403 — intervention group
Group type: COMPARATOR
Intervention: rosuvastatin 40 mg
Number of subjects: 25
Study 16027403 — intervention group
Group type: COMPARATOR
Intervention: rosuvastatin 10 mg, increased to 80 mg if INR <3
Number of subjects: 25
Study 12036422 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 0
Study 9564459 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 74
Study 9564459 — intervention group
Group type: EXPERIMENTAL
Intervention: Infected symptomatic subjects
Number of subjects: 74
Study 9564459 — intervention group
Group type: EXPERIMENTAL
Intervention: Infected subjects
Number of subjects: 74
Study 9564459 — intervention group
Group type: COMPARATOR
Intervention: Sham-inoculated subjects
Number of subjects: 74
Study 7605864 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily and amoxycillin 500 mg three times daily
Number of subjects: 54
Study 7605864 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 40 mg once daily and clarithromycin 500 mg three times daily
Number of subjects: 54
Study 7605864 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 54
Study 1965344 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine treatment (0.58 gamma/kg weight/min after a 12.3 gamma/kg weight bolus for 5 days)
Number of subjects: 39
Study 1965344 — intervention group
Group type: COMPARATOR
Intervention: Control group (no calcium entry blocker)
Number of subjects: 39
Study 1965344 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine treatment
Number of subjects: 39
Study 344835 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated serum inhibitor-resistant influenza B vaccine (R75)
Number of subjects: 43
Study 344835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 31151100 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective neurosurgery procedures rated by attending neurosurgeons using a need for surgery (NFS) score.
Number of subjects: 9156
Study 31151100 — intervention group
Group type: EXPERIMENTAL
Intervention: First-time surgery (craniotomy and spine surgery).
Number of subjects: 9156
Study 31151100 — intervention group
Group type: EXPERIMENTAL
Intervention: Spine surgeries with fusion procedures.
Number of subjects: 9156
Study 31151100 — intervention group
Group type: EXPERIMENTAL
Intervention: Redo surgery (all types).
Number of subjects: 9156
Study 28264570 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcination at various temperatures (specific temperatures not provided)
Number of subjects: 5
Study 28264570 — intervention group
Group type: COMPARATOR
Intervention: Comparison of sample distributions at each temperature (100, 250, 500, and 750 particles)
Number of subjects: 5
Study 26341595 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe3O4@PDA
Number of subjects: 0
Study 26341595 — intervention group
Group type: COMPARATOR
Intervention: Fe3O4@C
Number of subjects: 0
Study 23237679 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 2839
Study 23237679 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 2839
Study 23237679 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS) within 7 days
Number of subjects: 2839
Study 23237679 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA) within 7 days
Number of subjects: 2839
Study 23237679 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS) between 8 and 14 days
Number of subjects: 2839
Study 23237679 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA) between 8 and 14 days
Number of subjects: 2839
Study 23237679 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS) after 14 days
Number of subjects: 2839
Study 23237679 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA) after 14 days
Number of subjects: 2839
Study 20605604 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg of ropivacaine (group I)
Number of subjects: 60
Study 20605604 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg of ropivacaine (group D)
Number of subjects: 60
Study 20605604 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl use and frequency of pushing a button (FPB) for bolus PCA (group I)
Number of subjects: 60
Study 20605604 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl use and frequency of pushing a button (FPB) for bolus PCA (group D)
Number of subjects: 60
Study 20605604 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group C)
Number of subjects: 60
Study 19959435 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous-intensity PA
Number of subjects: 337
Study 19959435 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity PA
Number of subjects: 337
Study 19959435 — intervention group
Group type: COMPARATOR
Intervention: Vigorous-intensity PA and Moderate-intensity PA
Number of subjects: 337
Study 17287914 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting trocars
Number of subjects: 30
Study 17287914 — intervention group
Group type: COMPARATOR
Intervention: Blunt trocars
Number of subjects: 30
Study 14724302 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 2159
Study 14724302 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2159
Study 11578014 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-IFN-gamma
Number of subjects: 30
Study 11578014 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-TNF-alpha
Number of subjects: 30
Study 11578014 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 9692113 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-Wright meter
Number of subjects: 309
Study 9692113 — intervention group
Group type: EXPERIMENTAL
Intervention: Assess meter
Number of subjects: 309
Study 9692113 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmo-graph meter
Number of subjects: 309
Study 9692113 — intervention group
Group type: EXPERIMENTAL
Intervention: Wright Pocket meter
Number of subjects: 309
Study 9692113 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-range PFMs
Number of subjects: 309
Study 9692113 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-range PFMs
Number of subjects: 309
Study 9692113 — intervention group
Group type: EXPERIMENTAL
Intervention: All PFMs
Number of subjects: 309
Study 7838617 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional-Pulmonary Function Score (NPFS)
Number of subjects: 21
Study 7838617 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Function Score (PFS)
Number of subjects: 21
Study 7838617 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual PFT parameters
Number of subjects: 21
Study 7838617 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent Ideal Body Weight (%IBW)
Number of subjects: 21
Study 7838617 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaerobic Performance (AP)
Number of subjects: 21
Study 2977392 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin administered with food (moderate breakfast)
Number of subjects: 18
Study 2977392 — intervention group
Group type: COMPARATOR
Intervention: Acitretin administered during a complete fast
Number of subjects: 18
Study 31987975 — intervention group
Group type: EXPERIMENTAL
Intervention: PENTOCLO (pentoxifylline 800 mg, tocopherol 1000 mg, clodronate 1600 mg 5 days per week)
Number of subjects: 59
Study 31987975 — intervention group
Group type: COMPARATOR
Intervention: Triple placebo
Number of subjects: 59
Study 31987975 — intervention group
Group type: EXPERIMENTAL
Intervention: PENTOCLO
Number of subjects: 59
Study 31987975 — intervention group
Group type: EXPERIMENTAL
Intervention: PENTOCLO and Triple placebo
Number of subjects: 59
Study 31530075 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel transosseous device
Number of subjects: 70
Study 28653319 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal ropivacaine 15 mg
Number of subjects: 270
Study 28653319 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal ropivacaine
Number of subjects: 270
Study 26126940 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 4.0 mg/kg
Number of subjects: 134
Study 26126940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 23540442 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA 5 mg/kg continuous infusion over 24 hours
Number of subjects: 37
Study 23540442 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 37
Study 21696957 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen detected invasive cancer with ≥ 30 mm size
Number of subjects: 232
Study 21696957 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen detected invasive cancer with histological grade 3
Number of subjects: 232
Study 21696957 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen detected invasive cancer with heavily node positive (4 or more positive nodes)
Number of subjects: 232
Study 21696957 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen detected invasive cancer with vascular invasion positive
Number of subjects: 232
Study 21696957 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen detected invasive cancer displaying mammographic comedo calcification
Number of subjects: 232
Study 19558398 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding trials to participants' ERP averages (specifically 2 random trials added).
Number of subjects: 53
Study 19558398 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal reliability of the ERN and Pe after adding trials.
Number of subjects: 53
Study 19558398 — intervention group
Group type: EXPERIMENTAL
Intervention: Signal-to-noise ratio of the ERN and Pe after adding trials.
Number of subjects: 53
Study 16401916 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg bid and diclofenac sodium 75 mg for 2-3 weeks (group 1)
Number of subjects: 97
Study 16401916 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group 2)
Number of subjects: 97
Study 16401916 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin and diclofenac in histologically determined cancer cases (group 1)
Number of subjects: 97
Study 16401916 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin and diclofenac in BPH and prostatitis cases (group 1)
Number of subjects: 97
Study 14595084 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate HCL (MPH) at 36 mg or 54 mg
Number of subjects: 47
Study 14595084 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate HCL (MPH) at 36 mg or lower
Number of subjects: 47